Contact:
Devinder Bawa, President and CEO
Phone: 240.350.1110
Hemodyne (Bethesda, MD) announced the addition of two new directors to its Board. Mr. Bruno Borganti has been appointed to a two-year term and will assist the Company in marketing and sales. Mr. Borganti is President, Chief Executive Officer and founder of HemoDiagnostica, LLC, a provider of clinical chemistry coagulation and hematology systems to the physician laboratory market. He has over 25 years global experience across many sectors of the healthcare industry, including medical devices and analytical instrumentation. Most recently with Fisher Diagnostics, a division of Fisher Healthcare a leading provider of healthcare products, Mr. Borganti was responsible for the international business and distribution. He also served in several positions such as Director of Business Development and Director of Marketing for Mallinckrodt Medical Inc., a division of Tyco; during his 10 years tenure at Mallinckrodt his responsibilities included introducing innovative medical devices such portable blood gas analyzers, anesthesia and respiratory airways management devices in Europe, Japan and the United States.
Ms. Janet Willinger has also been appointed to a two-year term. Ms. Willinger has held leadership positions in healthcare for 20 years, including serving as marketing leader for a nationally recognized healthcare system. She has also led marketing efforts for a leading national physician group. Ms. Willinger has led organizations with a mission to improve children’s health and education at both the local and state levels in Virginia.
In making the announcement, Hemodyne CEO Devinder S. Bawa stated: “I am excited for the Company and our shareholders to have these two terrific additions to our Board of Directors. I look forward to working closely with both Bruno and Jan as we build Hemodyne. I also want to recognize the incredible contributions made to the Company by Robert Powers, who is retiring after serving on the Board for nearly ten years. It is safe to say that, without Bob’s help and guidance, Hemodyne would not have progressed to this stage. All shareholders owe him a debt of gratitude for his tireless service. He will be missed.”
Hemodyne, Inc. is an early stage medical device company that has developed the leading platelet testing system in the world. Hemodyne’s point of care Hemostasis Analysis System (HAS) will revolutionize patient care in two ways. First, the HAS will allow physicians to finally administer and manage drug therapy for cardiac, stroke, surgical, renal and hemophilia patients with accuracy and certainty. Second, the HAS will also substantially improve physicians’ ability to gauge bleeding risk pre-surgically. Effective monitoring of these drug therapies, as well as gauging surgical bleeding risk, via true platelet function assessment, is a substantial unmet clinical need and current diagnostic tools do not provide adequate guidance to physicians. The lack of sufficient clinical information often leads to dangerous and expensive complications. Assessment of platelet function is the only means of accurately determining a patient’s exposure to excessive bleeding or clotting.